逸漠生物构建可靠的细胞资源平台。涵盖细胞系、原代细胞、标记细胞、耐药细胞及培养相关产品
细胞资源平台
咨询热线:400-080-3389
CERS2 knockout HeLa cell line

CERS2 knockout HeLa cell line

产品货号:IMKO-H032

产品规格:1×106cells/T25或1mL冻存管

生长特性:贴壁生长

细胞形态:上皮细胞样

培养体系:90%MEM+10% FBS+1%PS

价格:9000元

搭配培养体系
细胞基本属性
产品名称CERS2 knockout HeLa cell line
产品货号IMKO-H032
产品规格1×106cells/T25或1mL冻存管
储存及运输干冰运输;储存在液氮中
产品分类293T细胞
物种
修饰基因CERS2
修饰类型基因敲除
转导方法CRISPR/Cas9
克隆类型纯化克隆
细胞鉴定通过遗传学方法确认CERS2基因敲除
细胞形态上皮细胞样
生长特性贴壁生长
培养体系90%MEM+10% FBS+1%PS
传代比例1:2至1:3
传代周期每周3次
培养条件气相:95%空气+5%二氧化碳;温度:37℃
冻存条件无血清冻存液,液氮储存

补充内容

CERS2(Cholesterol ester storage disease, type 2)是一种罕见的遗传性疾病,属于胆固醇酯储存疾病的一种。这种疾病是由于CERS2基因突变导致的,它编码的是一种名为胆固醇酯储存蛋白2(Cholesterol ester storage protein 2)的蛋白质。这种蛋白质在细胞内参与胆固醇酯的代谢过程。 CERS2基因突变会导致胆固醇酯在细胞内积累,影响细胞的正常功能。这种疾病可能会导致一系列的症状,包括肝脾大、脂质代谢异常、神经系统问题等。CERS2疾病的诊断通常需要通过基因检测来确认CERS2基因的突变。目前,对于这种疾病的治疗主要是对症治疗,包括控制血脂水平、管理肝功能异常等。

构建方法图片2.jpg
CERS2基因敲除细胞系构建通常涉及的步骤

1.设计sgRNA:设计单链RNA(sgRNA),用于与Cas9蛋白结合,形成CRISPR-Cas9复合物,识别并切割CERS2基因的特定区域。 

2.构建质粒:将设计好的sgRNA序列插入质粒载体中,通常是在质粒中包含Cas9基因,通过细胞内的转染等方式将构建好的质粒引入目标细胞。 

3.细胞转染:将构建好的质粒转染到目标细胞中,使得CRISPR-Cas9复合物能够识别并切割CERS2基因的特定区域,引发基因编辑。 

4.筛选纯化:通过细胞培养基中添加适当的选择性抗生素等筛选方法,筛选出成功敲除CERS2基因的细胞克隆。 

5.验证敲除:通过PCR、Western blot等技术验证敲除效果,确认目标基因已经被成功敲除。

CERS2基因的基本信息

Species

Gene Symbol

Gene ID

GenBank Accession

Transcript

Human (Homo sapiens)

CERS2

29956

NM_181746.4

NP_859530.1

关于基因Official SymbolCERS2
Previous SymbolCERS2
Official Full NameCeramide Synthase 2
SynonymsLAG1 longevity assurance Human (Homo sapiens) (Homo sapiens)log 2, LASS2, TSC4, SP260
Location1q21.3
Gene TypeProtein-coding
Uniprot IDD3DV06, Q5SZE5, Q96G23, Q9HD96, Q9NW79
Pathway/LibraryCeramide biosynthesis pathway
Gene SummaryThe protein encoded by this gene is a member of the TNF receptor associated factor (TRAF) protein family. TRAF proteins associate with, and mediate the signal transduction from members of the TNF receptor superfamily. This protein directly interacts with TNF receptors, and forms a heterodimeric complex with TRAF1. This protein is required for TNF-alpha-mediated activation of MAPK8/JNK and NF-kappaB. The protein complex formed by this protein and TRAF1 interacts with the inhibitor-of-apoptosis proteins (IAPs), and functions as a mediator of the anti-apoptotic signals from TNF receptors. The interaction of this protein with TRADD, a TNF receptor associated apoptotic signal transducer, ensures the recruitment of IAPs for the direct inhibition of caspase activation. BIRC2/c-IAP1, an apoptosis inhibitor possessing ubiquitin ligase activity, can unbiquitinate and induce the degradation of this protein, and thus potentiate TNF-induced apoptosis. Multiple alternatively spliced transcript variants have been found for this gene, but the biological validity of only one transcript has been determined. [provided by RefSeq, Jul 2008]

相关问题

培养指南

培养操作视频

相关产品